Cost Of Revenue - Maat Pharma SA (PAR:MAAT) - Alpha Spread
M

Maat Pharma SA
PAR:MAAT

Watchlist Manager
Maat Pharma SA
PAR:MAAT
Watchlist
Price: 7.3 EUR 2.24% Market Closed
Market Cap: 101.4m EUR
Have any thoughts about
Maat Pharma SA?
Write Note

Maat Pharma SA
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Maat Pharma SA
Cost of Revenue Peer Comparison

Comparables:
VLA
NANO
IPH
GNFT
ALERS

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
M
Maat Pharma SA
PAR:MAAT
Cost of Revenue
-€573k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Cost of Revenue
-€135.8m
CAGR 3-Years
-26%
CAGR 5-Years
-26%
CAGR 10-Years
-23%
Nanobiotix SA
PAR:NANO
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innate Pharma SA
PAR:IPH
Cost of Revenue
-€3m
CAGR 3-Years
9%
CAGR 5-Years
4%
CAGR 10-Years
14%
Genfit SA
NASDAQ:GNFT
Cost of Revenue
-€2.2m
CAGR 3-Years
-1%
CAGR 5-Years
-3%
CAGR 10-Years
-5%
Eurobio Scientific SA
PAR:ALERS
Cost of Revenue
-€68.8m
CAGR 3-Years
4%
CAGR 5-Years
-16%
CAGR 10-Years
-16%

See Also

What is Maat Pharma SA's Cost of Revenue?
Cost of Revenue
-573k EUR

Based on the financial report for Dec 31, 2023, Maat Pharma SA's Cost of Revenue amounts to -573k EUR.

What is Maat Pharma SA's Cost of Revenue growth rate?
Cost of Revenue CAGR 1Y
-69%

Over the last year, the Cost of Revenue growth was -69%.

Back to Top